{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:37:31Z","timestamp":1794641851952,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["2R01CA178394"],"award-info":[{"award-number":["2R01CA178394"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["F31CA236434"],"award-info":[{"award-number":["F31CA236434"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","id":[{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1S10OD01630"],"award-info":[{"award-number":["1S10OD01630"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012636","name":"New York State Stem Cell Science","doi-asserted-by":"publisher","award":["C029154"],"award-info":[{"award-number":["C029154"]}],"id":[{"id":"10.13039\/100012636","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pershing Square Sohn Cancer Research Alliance, Irma T. Hirschl Trust","id":[{"id":"https:\/\/ror.org\/01yaqvf46","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Deregulation of the BCL-2 family interaction network ensures cancer resistance to apoptosis and is a major challenge to current treatments. Cancer cells commonly evade apoptosis through upregulation of the BCL-2 anti-apoptotic proteins; however, more resistant cancers also downregulate or inactivate pro-apoptotic proteins to suppress apoptosis. Here, we find that apoptosis resistance in a diverse panel of solid and hematological malignancies is mediated by both overexpression of BCL-XL and an unprimed apoptotic state, limiting direct and indirect activation mechanisms of pro-apoptotic BAX. Both survival mechanisms can be overcome by the combination of an orally bioavailable BAX activator, BTSA1.2 with Navitoclax. The combination demonstrates synergistic efficacy in apoptosis-resistant cancer cells, xenografts, and patient-derived tumors while sparing healthy tissues. Additionally, functional assays and genomic markers are identified to predict sensitive tumors to the combination treatment. These findings advance the understanding of apoptosis resistance mechanisms and demonstrate a novel therapeutic strategy for cancer treatment.<\/jats:p>","DOI":"10.1038\/s41467-022-28741-7","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T06:06:11Z","timestamp":1646633171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":193,"title":["Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer"],"prefix":"10.1038","volume":"13","author":[{"given":"Andrea","family":"Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis E.","family":"Reyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadege","family":"Gitego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Miranda-Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Ulrik","family":"Nordstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi-Rao","family":"Narayanagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-3761","authenticated-orcid":false,"given":"Eduardo","family":"Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-8477","authenticated-orcid":false,"given":"Aristotelis","family":"Tsirigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6319-8331","authenticated-orcid":false,"given":"Evripidis","family":"Gavathiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"28741_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"28741_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","volume":"16","author":"ARD Delbridge","year":"2016","unstructured":"Delbridge, A. R. D., Grabow, S., Strasser, A. & Vaux, D. L. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer 16, 99\u2013109 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"28741_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20, 175\u2013193 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"28741_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","volume":"5","author":"AN Hata","year":"2015","unstructured":"Hata, A. N., Engelman, J. A. & Faber, A. C. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 5, 475\u2013487 (2015).","journal-title":"Cancer Discov."},{"key":"28741_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gde.2010.12.001","volume":"21","author":"F Llambi","year":"2011","unstructured":"Llambi, F. & Green, D. R. Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr. Opin. Genet. Dev. 21, 12\u201320 (2011).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"28741_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle, R. J. & Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47\u201359 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"28741_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"28741_CR8","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1158\/1078-0432.CCR-14-0959","volume":"21","author":"H Brahmbhatt","year":"2015","unstructured":"Brahmbhatt, H., Oppermann, S., Osterlund, E. J., Leber, B. & Andrews, D. W. Molecular pathways: leveraging the BCL-2 interactome to kill cancer cells-mitochondrial outer membrane permeabilization and beyond. Clin. Cancer Res. 21, 2671\u20132676 (2015).","journal-title":"Clin. Cancer Res."},{"key":"28741_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc2297","volume":"8","author":"AG Letai","year":"2008","unstructured":"Letai, A. G. Diagnosing and exploiting cancer\u2019s addiction to blocks in apoptosis. Nat. Rev. Cancer 8, 121\u2013132 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"28741_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3538","volume":"13","author":"P Juin","year":"2013","unstructured":"Juin, P., Geneste, O., Gautier, F., Depil, S. & Campone, M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat. Rev. Cancer 13, 455\u2013465 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"28741_CR11","doi-asserted-by":"crossref","unstructured":"Vo, T.-T. & Letai, A. BH3-only proteins and their effects on cancer. in BCL-2 Protein Family (ed. Hetz, C.) vol. 687 49\u201363 (Springer New York, 2010).","DOI":"10.1007\/978-1-4419-6706-0_3"},{"key":"28741_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrc3711","volume":"14","author":"KT Bieging","year":"2014","unstructured":"Bieging, K. T., Mello, S. S. & Attardi, L. D. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev. Cancer 14, 359\u2013370 (2014).","journal-title":"Nat Rev. Cancer"},{"key":"28741_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","volume":"109","author":"C Mestre-Escorihuela","year":"2007","unstructured":"Mestre-Escorihuela, C. et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109, 271\u2013280 (2007).","journal-title":"Blood"},{"key":"28741_CR14","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1158\/1078-0432.CCR-07-5202","volume":"14","author":"FA Sinicrope","year":"2008","unstructured":"Sinicrope, F. A. et al. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin. Cancer Res. 14, 5810\u20135818 (2008).","journal-title":"Clin. Cancer Res."},{"key":"28741_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1615\/CritRevEukarGeneExpr.v22.i2.40","volume":"22","author":"H Harada","year":"2012","unstructured":"Harada, H. & Grant, S. Targeting the regulatory machinery of BIM for cancer therapy. Crit. Rev. Eukaryot Gene Exp. 22, 117\u2013129 (2012).","journal-title":"Crit. Rev. Eukaryot Gene Exp."},{"key":"28741_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677\u2013681 (2005).","journal-title":"Nature"},{"key":"28741_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"28741_CR18","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."},{"key":"28741_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477\u2013482 (2016).","journal-title":"Nature"},{"key":"28741_CR20","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson, J. D. et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra40 (2015).","journal-title":"Sci. Transl. Med."},{"key":"28741_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New England J. Med. 374, 311\u2013322 (2016).","journal-title":"New England J. Med."},{"key":"28741_CR22","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163\u20133169 (2012).","journal-title":"Clin. Cancer Res."},{"key":"28741_CR23","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel, S. et al. AMG 176, a selective MCL1 inhibitor, is effective in hematological cancer models alone and in combination with established therapies. Cancer Discov. 8, 1582\u20131597 (2018).","journal-title":"Cancer Discov."},{"key":"28741_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft, M. F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389\u2013399 (2006).","journal-title":"Cancer Cell"},{"key":"28741_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cbpa.2017.06.014","volume":"39","author":"TP Garner","year":"2017","unstructured":"Garner, T. P., Lopez, A., Reyna, D. E., Spitz, A. Z. & Gavathiotis, E. Progress in targeting the BCL-2 family of proteins. Curr. Opin. Chem. Biol. 39, 133\u2013142 (2017).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"28741_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375\u2013388 (2006).","journal-title":"Cancer Cell"},{"key":"28741_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron, A. E. et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat. Commun. 9, 5341 (2018).","journal-title":"Nat. Commun."},{"key":"28741_CR28","doi-asserted-by":"publisher","first-page":"eaam7049","DOI":"10.1126\/scitranslmed.aam7049","volume":"9","author":"D Merino","year":"2017","unstructured":"Merino, D. et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci. Transl. Med. 9, eaam7049 (2017).","journal-title":"Sci. Transl. Med."},{"key":"28741_CR29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino, D. et al. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell 34, 879\u2013891 (2018).","journal-title":"Cancer Cell"},{"key":"28741_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 9, 890\u2013909 (2019).","journal-title":"Cancer Discov."},{"key":"28741_CR31","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.tcb.2016.07.002","volume":"26","author":"MPA Luna-Vargas","year":"2016","unstructured":"Luna-Vargas, M. P. A. & Chipuk, J. E. Physiological and pharmacological control of BAK, BAX, and beyond. Trends Cell Biol. 26, 906\u2013917 (2016).","journal-title":"Trends Cell Biol."},{"key":"28741_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/science.290.5493.989","volume":"290","author":"L Zhang","year":"2000","unstructured":"Zhang, L. Role of BAX in the apoptotic response to anticancer agents. Science 290, 989\u2013992 (2000).","journal-title":"Science"},{"key":"28741_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/nature07396","volume":"455","author":"E Gavathiotis","year":"2008","unstructured":"Gavathiotis, E. et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076\u20131081 (2008).","journal-title":"Nature"},{"key":"28741_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.molcel.2010.10.019","volume":"40","author":"E Gavathiotis","year":"2010","unstructured":"Gavathiotis, E., Reyna, D. E., Davis, M. L., Bird, G. H. & Walensky, L. D. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol. Cell 40, 481\u2013492 (2010).","journal-title":"Mol. Cell"},{"key":"28741_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.molcel.2009.09.030","volume":"36","author":"H Kim","year":"2009","unstructured":"Kim, H. et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell 36, 487\u2013499 (2009).","journal-title":"Mol. Cell"},{"key":"28741_CR36","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.tibs.2011.08.009","volume":"36","author":"LD Walensky","year":"2011","unstructured":"Walensky, L. D. & Gavathiotis, E. BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem. Sci. 36, 642\u2013652 (2011).","journal-title":"Trends Biochem. Sci."},{"key":"28741_CR37","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nchembio.995","volume":"8","author":"E Gavathiotis","year":"2012","unstructured":"Gavathiotis, E., Reyna, D. E., Bellairs, J. A., Leshchiner, E. S. & Walensky, L. D. Direct and selective small-molecule activation of proapoptotic BAX. Nat. Chem. Biol. 8, 639\u2013645 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"28741_CR38","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ccell.2017.09.001","volume":"32","author":"D.E Reyna","year":"2017","unstructured":"Reyna, D. E. et al. Direct activation of BAX by BTSA1 overcomes apoptosis resistance in acute myeloid leukemia. Cancer Cell 32, 490\u2013505.e10 (2017).","journal-title":"Cancer Cell"},{"key":"28741_CR39","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J. Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6, pl1 (2013).","journal-title":"Sci Signal"},{"key":"28741_CR40","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1182\/blood-2011-12-400929","volume":"119","author":"D M\u00e9rino","year":"2012","unstructured":"M\u00e9rino, D. et al. Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 119, 5807\u20135816 (2012).","journal-title":"Blood"},{"key":"28741_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-98","volume":"13","author":"B Wang","year":"2014","unstructured":"Wang, B. et al. The Bcl-2\/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer 13, 98 (2014).","journal-title":"Mol Cancer"},{"key":"28741_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ymeth.2013.04.006","volume":"61","author":"J Ryan","year":"2013","unstructured":"Ryan, J. & Letai, A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 61, 156\u2013164 (2013).","journal-title":"Methods"},{"key":"28741_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","volume":"12","author":"J Deng","year":"2007","unstructured":"Deng, J. et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12, 171\u2013185 (2007).","journal-title":"Cancer Cell"},{"key":"28741_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5935","volume":"5","author":"M Xin","year":"2014","unstructured":"Xin, M. et al. Small-molecule Bax agonists for cancer therapy. Nat Commun 5, 4935 (2014).","journal-title":"Nat Commun"},{"key":"28741_CR45","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1182\/blood-2008-05-156851","volume":"113","author":"KF Whitecross","year":"2009","unstructured":"Whitecross, K. F. et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 113, 1982\u20131991 (2009).","journal-title":"Blood"},{"key":"28741_CR46","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder, S. M. et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 118, 1663\u20131674 (2011).","journal-title":"Blood"},{"key":"28741_CR47","doi-asserted-by":"publisher","first-page":"e2342","DOI":"10.1038\/cddis.2016.233","volume":"7","author":"A-L Scherr","year":"2016","unstructured":"Scherr, A.-L. et al. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 7, e2342 (2016).","journal-title":"Cell Death Dis."},{"key":"28741_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1158\/1535-7163.MCT-04-0162","volume":"4","author":"H Zhu","year":"2005","unstructured":"Zhu, H. et al. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol. Cancer Ther. 4, 451\u2013456 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"28741_CR49","doi-asserted-by":"crossref","unstructured":"Dunne, P. D. et al. Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer. Oncotarget 9, (2018).","DOI":"10.1101\/207639"},{"key":"28741_CR50","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/sj.bjc.6601254","volume":"89","author":"V Wacheck","year":"2003","unstructured":"Wacheck, V. et al. Bcl-xL antisense oligonucleotides radiosensitise colon cancer cells. Br. J Cancer 89, 1352\u20131357 (2003).","journal-title":"Br. J Cancer"},{"key":"28741_CR51","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/10428194.2020.1845332","volume":"62","author":"S de Vos","year":"2021","unstructured":"de Vos, S. et al. Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk. Lymphoma 62, 810\u2013818 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"28741_CR52","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/cdd.2011.17","volume":"18","author":"PN Kelly","year":"2011","unstructured":"Kelly, P. N. & Strasser, A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 18, 1414\u20131424 (2011).","journal-title":"Cell Death Differ"},{"key":"28741_CR53","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks, E. D. Venetoclax: first global approval. Drugs 76, 979\u2013987 (2016).","journal-title":"Drugs"},{"key":"28741_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212574","volume":"8","author":"LM Ju\u00e1rez-Salcedo","year":"2019","unstructured":"Ju\u00e1rez-Salcedo, L. M., Desai, V. & Dalia, S. Venetoclax: evidence to date and clinical potential. DIC 8, 1\u201313 (2019).","journal-title":"DIC"},{"key":"28741_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ 25, 65\u201380 (2018).","journal-title":"Cell Death Differ"},{"key":"28741_CR56","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1172\/JCI35437","volume":"118","author":"MS Cragg","year":"2008","unstructured":"Cragg, M. S. et al. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest. 118, 3651\u20133659 (2008).","journal-title":"J. Clin. Invest."},{"key":"28741_CR57","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1371\/journal.pmed.0040316","volume":"4","author":"MS Cragg","year":"2007","unstructured":"Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S. & Strasser, A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4, e316 (2007).","journal-title":"PLoS Med."},{"key":"28741_CR58","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1371\/journal.pmed.0040294","volume":"4","author":"Y Gong","year":"2007","unstructured":"Gong, Y. et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4, e294 (2007).","journal-title":"PLoS Med."},{"key":"28741_CR59","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan, S. et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat. Med. 25, 1938\u20131947 (2019).","journal-title":"Nat. Med."},{"key":"28741_CR60","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/onc.2016.241","volume":"36","author":"YH Sheng","year":"2017","unstructured":"Sheng, Y. H. et al. MUC13 protects colorectal cancer cells from death by activating the NF-\u03baB pathway and is a potential therapeutic target. Oncogene 36, 700\u2013713 (2017).","journal-title":"Oncogene"},{"key":"28741_CR61","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli, G. Y. et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32, 2866\u20132868 (2016).","journal-title":"Bioinformatics"},{"key":"28741_CR62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1074\/jbc.M115.680918","volume":"291","author":"O Uchime","year":"2016","unstructured":"Uchime, O. et al. Synthetic antibodies inhibit Bcl-2-associated X protein (BAX) through blockade of the N-terminal activation site. J. Biol. Chem. 291, 89\u2013102 (2016).","journal-title":"J. Biol. Chem."},{"key":"28741_CR63","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero, J. et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160, 977\u2013989 (2015).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28741-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28741-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28741-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:16:55Z","timestamp":1669288615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28741-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["28741"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-28741-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"11 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.G., D.E.R., F.K. are inventors on patent applications regarding small molecule BAX activators submitted by Albert Einstein College of Medicine. These patent applications are licensed to BAKX Therapeutics. E.G. is a co-founder and scientific advisor of BAKX Therapeutics, Stelexis Therapeutics, and Selphagy Therapeutics now part of Life Biosciences. E. Vilar has a consulting and advisory role with Janssen Research and Development. None of the above companies have sponsored this research. No potential conflicts of interest were disclosed by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1199"}}